EA
ADVM

Emerald Acquisition’s Adverum Biotechnologies ADVM Stock Holding History

Emerald Acquisition’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$446K Buy
+10,833
New +$411K ﹤0.01% 2482

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Emerald Acquisition's ADVM Position: Q3 2016 in Review

Emerald Acquisition opened a new position in Adverum Biotechnologies (ADVM) in Q3 2016: 10,833 shares worth $446K. The stake represents ﹤0.01% of the portfolio and ranks #2482 among its holdings.

76 funds tracked by Wall St. Rank hold ADVM as of Q3 2016.

  • Emerald Acquisition held 10,833 shares of Adverum Biotechnologies worth $446K as of Q3 2016.
  • Adverum Biotechnologies was a new Emerald Acquisition position in Q3 2016.
  • Adverum Biotechnologies made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2482 holding.
  • 76 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.